To Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants with Type 2 Diabetes Mellitus who have Obesity or Overweight and Sleep Apnoea: A Randomized, Double-Blind, Placebo-Controlled Trial.
You are eligible if you are:
- >18 years old and:
- are overweight (BMI>27kg/m2)
- have type 2 diabetes
- have a history of at least one dietary effort to lose body weight
- previously diagnosed with obstructive sleep apnoea
A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once-Daily Oral LY3502970 Compared with Placebo in Adult Participants with Obesity or Overweight and Type 2 Diabetes
You are eligible if you are >18 years old and:
- are overweight (BMI>27kg/m2)
- have type 2 diabetes
- have a history of at least one dietary effort to lose body weight
A Randomized, Double-Blind, Phase 3 Study to Investigate the Efficacy and Safety of LY3437943 Once Weekly Compared to Placebo in Participants with Severe Obesity and Established Cardiovascular Disease
You are eligible if you are >18 years old and:
- are overweight (BMI>35kg/m2)
- have established cardiovascular disease and can answer yes to one of the following:
- prior myocardial infarction
- prior stroke
- peripheral arterial vascularization
- amputation due to vascular disease
- symptomatic vascular disease.
- have a history of at least one dietary effort to lose body weight
The Metformin Aneurysm Trial (MAT)
An investigator initiated and conducted, multicentre, international, double-blinded, placebo-controlled, parallel-group, randomised controlled trial to determine the effect of metformin on abdominal aortic aneurysm (AAA) associated events, including AAA repair and AAA mortality (due to aneurysm rupture).
You may be eligible if you:
- have an abdominal aortic aneurysm
- are aged between 18 – 79 years old
- are not taking metformin
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Tirzepatide on the Reduction of Morbidity and Mortality in Adults with Obesity
You are eligible if you:
- are overweight (BMI>27kg/m2)
- do not have diabetes
- have established cardiovascular disease (coronary artery disease, cerebrovascular disease, or peripheral arterial disease) OR can answer yes to two of the following:
- are a current smoker
- have high cholesterol
- have high blood pressure
- have kidney disease
- have prediabetes
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study to Investigate the Effect of Retatrutide on the Incidence of Major Adverse Cardiovascular Events and the Decline in Kidney Function in Participants with Body Mass Index ≥27 kg/m2 and Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease
You are eligible if you:
- have a BMI of 27 kg/m2
or more - are aged 45 years or older
- have heart disease
- have kidney disease
- have type 2 diabetes or not, and your HbA1c
levels are less than 10 percent.
Investigation of the safety and efficacy of once weekly NNC0519-0130 in participants with type 2 diabetes – a dose finding study
You are eligible if you:
- Have type 2 diabetes, and a BMI≥ 23
- On metformin with or without SGLT2 inhibitor
- HbA1c of 7.5-10.0%
- Are 18-75 Years
- If female, be of non-childbearing potential
- Be able and willing to adhere to study procedure.
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus
You are eligible if you:
- are 18 years of age or older
- have a body mass index of 27kg/m² or more (overweight or obesity)
- have been diagnosed with T2DM for at least 6 months and are receiving treatment for it
- have made at least 1 attempt to lose weight through nutrition and physical activity, but did not meet your/their goal.